CB1400, Patented By Canopus BioPharma, Prevents Tumor Growth And Enhances The Anti-Tumor Effects Of Cisplatin And Cetuximab Erbitux
Added: 21 èþíÿ 2008
Last relative articles:
- State-of-the-Art Lecture: What Are The Most Important Ongoing Clinical Trials In Urologic Oncology Worldwide?
- 5 Top Young Clinical Investigators Receive Damon Runyon Cancer Research Foundation Awards
- State-of-the-Art Lecture: Aptomers Of Nanotechnology - Reported From The Annual Meeting Of The American Urological Association
- AAD, MLB And MLB Players Association Play Sun Smart To Strike Out Skin Cancer
- Oncolin Therapeutics Announces Its Cancer Technology Will Be Presented At The 20th EORTC-NCI-AACR Symposium
- Merck Applies To Extend Use Of Erbitux For 1st-Line Head And Neck Cancer In Europe
- Melanoma Is On The Rise In Women
- Indiana University Simon Cancer Center Priority: Reduce Cancer Incidences, Mortality Among State's Diverse Populations
- Obesity Surgery May Reduce Cancer Risk
- Japan Approves CyberKnife System For Extracranial Use - Non-Invasive Treatment Alternative For Tumors Anywhere In The Body
Comments: [0] / Post comment:
08 Jan 2009 07:54:47
Alexion Settles Legal Dispute - Xconomy
Alexion Settles Legal Dispute Xconomy, MA - Alexion Pharmaceuticals (NASDAQ:ALXN) reports it will pay $25 million to PDL BioPharma (NASDAQ:PDLI) to license a patent related to humanizing antibodies ... Alexion Pharmaceutical settles patent dispute
08 Jan 2009 07:09:00
Ondine Biopharma Announces Management and Board Changes - CNW Telbec (Communiqué de presse)
Ondine Biopharma Announces Management and Board Changes CNW Telbec (Communiqué de presse), Canada - For further information: Carolyn Cross, President and Chief Executive Officer, Ondine Biopharma Corporation, (604) 669-0555, ccross ondinebiopharma.com; ...
07 Jan 2009 22:00:46
DOR BioPharma Obtains Fast Track Designation for DOR201 in the ... - MSNBC
DOR BioPharma Obtains Fast Track Designation for DOR201 in the ... MSNBC - DOR BioPharma , Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and ...
07 Jan 2009 22:00:29
PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00 ... - MSNBC
Earthtimes (press release) PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00 ... MSNBC - INCLINE VILLAGE, NV - PDL BioPharma , Inc. (PDL) (NASDAQ: PDLI) announced today the adjustment to the conversion rate for its 2.00% Convertible Senior Notes ... Facet Biotech to cut 80 jobs, narrow focus on oncology Facet Biotechnology to cut 78 workers Silicon Valley San Jose ... Facet Biotech Announces Restructuring and Provides Estimate of ... -
07 Jan 2009 14:19:34
Ondine Biopharma names Cale Street VP of Research, Ondine Research ... - RTT News
Ondine Biopharma names Cale Street VP of Research, Ondine Research ... RTT News, NY - (RTTNews) - Ondine Biopharma Corp. (OBP.TO: News ,OBP.L: News ) announced reorganization to its senior management team. Ondine said that Cale Street has ...
07 Jan 2009 09:36:01
ONI BioPharma Taps Dr. Martin Handfield as Director of Research ... - Trading Markets (press release)
ONI BioPharma Taps Dr. Martin Handfield as Director of Research ... Trading Markets (press release), CA - In a release, the company noted that prior to joining ONI BioPharma , Dr. Handfield was a tenured faculty member at the Center for Molecular Microbiology and ...
06 Jan 2009 14:21:01
DOR BioPharma Obtains Fast Track Designation for DOR201 in the ... - Trading Markets (press release)
DOR BioPharma Obtains Fast Track Designation for DOR201 in the ... Trading Markets (press release), CA - DOR BioPharma , Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and ... FDA OKs Design of 2nd Phase III OrBec Trial to Begin by June DOR BioPharma gets SPA Clearance From FDA to begin Confirmatory ... Dor wins FDA clearance to initiate Phase III graft-versus-host ...
06 Jan 2009 14:09:29
Endo to acquire biopharma firm Indevus for $370 million - domain-B
Endo to acquire biopharma firm Indevus for $370 million domain-B, India - Endo said it may spend up to $637 million in the first biopharma acquisition of the year as the industry consolidates. Endo will commence a tender offer to ... What Can Brown Do For Merck? Endo Shifts Gears With Indevus
06 Jan 2009 13:41:52
PDL BioPharma announces adjustment to conversion rate for 2 ... - RTT News
PDL BioPharma announces adjustment to conversion rate for 2 ... RTT News, NY - (RTTNews) - PDL BioPharma , Inc. (PDLI: News ) announced the adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012. ... Facet Biotech chief business officer terminated Silicon Valley ...
05 Jan 2009 14:43:58
PDL BioPharma, Alexion settle patent dispute - Forbes
PDL BioPharma , Alexion settle patent dispute Forbes, NY - AP , 01.05.09, 07:31 AM EST PDL BioPharma Inc. and Alexion Pharmaceuticals Inc. said Monday they settled a patent dispute over the blood disorder drug ... Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute Alexion settles lawsuit over patent for anemia treatment Alexion Pharmaceuticals to pay $25M in patent dispute